Literature DB >> 21494763

Expression of pERK and pAKT in human astrocytomas: correlation with IDH1-R132H presence, vascular endothelial growth factor, microvascular characteristics and clinical outcome.

Angelica A Saetta1, Georgia Levidou, Elias A El-Habr, Ioannis Panayotidis, Vassilis Samaras, Irene Thymara, Stratigoula Sakellariou, Efstathios Boviatsis, Efstratios Patsouris, Penelope Korkolopoulou.   

Abstract

Although pERK and pAKT are reportedly activated in various neoplasms, little information is available about their significance in astrocytomas. Paraffin-embedded tissue from 82 patients with diffuse infiltrating astrocytomas (grades II to IV) was investigated for the association of pERK and pAKT activation with clinicopathological features, vascular endothelial growth factor (VEGF), isocitrate dehydrogenase 1 and microvascular parameters. Nuclear pERK labelling index (LI) increased with increasing cytoplasmic pERK LI and nuclear and cytoplasmic pAKT LI (p = 0.0019, p = 0.0260 and p = 0.0012, respectively). Accordingly, cytoplasmic pERK increased with increasing levels of nuclear (p = 0.0001) and marginally with cytoplasmic pAKT LI (p = 0.0526). Nuclear and cytoplasmic pERK LI and nuclear pAKT LI were positively correlated with tumour histological grade (p = 0.0040, p = 0.0238 for pERK and p = 0.0004 for pAKT, respectively). VEGF expression was correlated with nuclear pERK (p = 0.0099) and nuclear pAKT LI (p = 0.0002). Interestingly, pERK cytoplasmic LI increased with microvessel calibre (p = 0.0287), whereas pAKT nuclear LI was marginally related to microvessel density (p = 0.0685). The presence of IDH1-R132H was related only to histological grade and lower microvessel calibre. Multivariate survival analysis in the entire cohort selected cytoplasmic pAKT LI (p = 0.045), histological grade, microvessel calibre (p = 0.028), patients' age, gender and surgical excision as independent predictors of survival. Moreover, in glioblastomas, pERK nuclear LI emerged as a favourable prognosticator in the presence of IDH1-R132H. pERK and pAKT in astrocytomas are interrelated and associated with tumour grade and angiogenesis. Moreover, the importance of cytoplasmic pAKT immunoexpression in patients' prognosis and nuclear pERK immunoexpression in glioblastomas is confirmed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21494763     DOI: 10.1007/s00428-011-1074-1

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  48 in total

Review 1.  Functional proteomics to dissect tyrosine kinase signalling pathways in cancer.

Authors:  Walter Kolch; Andrew Pitt
Journal:  Nat Rev Cancer       Date:  2010-08-19       Impact factor: 60.716

Review 2.  The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions.

Authors:  Seunghee Yoon; Rony Seger
Journal:  Growth Factors       Date:  2006-03       Impact factor: 2.511

Review 3.  Mitogen-activated protein kinase pathways.

Authors:  M J Robinson; M H Cobb
Journal:  Curr Opin Cell Biol       Date:  1997-04       Impact factor: 8.382

4.  A mouse model for glioma: biology, pathology, and therapeutic opportunities.

Authors:  E C Holland
Journal:  Toxicol Pathol       Date:  2000 Jan-Feb       Impact factor: 1.902

Review 5.  The Ras-ERK pathway: understanding site-specific signaling provides hope of new anti-tumor therapies.

Authors:  Fernando Calvo; Lorena Agudo-Ibáñez; Piero Crespo
Journal:  Bioessays       Date:  2010-05       Impact factor: 4.345

6.  The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.

Authors:  Arnab Chakravarti; Gary Zhai; Yoshiyuki Suzuki; Sormeh Sarkesh; Peter M Black; Alona Muzikansky; Jay S Loeffler
Journal:  J Clin Oncol       Date:  2004-05-15       Impact factor: 44.544

Review 7.  Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation.

Authors:  C J Marshall
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582

8.  Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions.

Authors:  Vered Givant-Horwitz; Ben Davidson; Philip Lazarovici; Erik Schaefer; Jahn M Nesland; Claes G Tropé; Reuven Reich
Journal:  Gynecol Oncol       Date:  2003-10       Impact factor: 5.482

9.  Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patients.

Authors:  C Le Page; I H Koumakpayi; M Alam-Fahmy; A-M Mes-Masson; F Saad
Journal:  Br J Cancer       Date:  2006-05-23       Impact factor: 7.640

10.  ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours.

Authors:  S Vicent; J M López-Picazo; G Toledo; M D Lozano; W Torre; C Garcia-Corchón; C Quero; J-C Soria; S Martín-Algarra; R G Manzano; L M Montuenga
Journal:  Br J Cancer       Date:  2004-03-08       Impact factor: 7.640

View more
  8 in total

1.  Complex interactions between the components of the PI3K/AKT/mTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma development.

Authors:  Elias A El-Habr; Georgia Levidou; Eleni-Andriana Trigka; Joanna Sakalidou; Christina Piperi; Ilenia Chatziandreou; Anastasia Spyropoulou; Rigas Soldatos; Georgia Tomara; Kalliopi Petraki; Vassilis Samaras; Athanasios Zisakis; Vassilis Varsos; George Vrettakos; Efstathios Boviatsis; Efstratios Patsouris; Angelica A Saetta; Penelope Korkolopoulou
Journal:  Virchows Arch       Date:  2014-08-22       Impact factor: 4.064

2.  Microfoci of malignant progression in diffuse low-grade gliomas: towards the creation of an intermediate grade in glioma classification?

Authors:  Zoé Pedeutour-Braccini; Fanny Burel-Vandenbos; Catherine Gozé; Coralie Roger; Audrey Bazin; Valérie Costes-Martineau; Hugues Duffau; Valérie Rigau
Journal:  Virchows Arch       Date:  2015-01-21       Impact factor: 4.064

3.  Overexpression of vascular endothelial growth factor indicates poor outcomes of glioma: a systematic review and meta-analysis.

Authors:  Wenjie Chen; Deshen He; Zuyun Li; Xin Zhang; Denghua Pan; Gang Chen
Journal:  Int J Clin Exp Med       Date:  2015-06-15

4.  Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis.

Authors:  Hairui Sun; Lianhu Yin; Showwei Li; Song Han; Guangrong Song; Ning Liu; Changxiang Yan
Journal:  J Neurooncol       Date:  2013-03-16       Impact factor: 4.130

5.  Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner.

Authors:  Panagiotis J Vlachostergios; Eleana Hatzidaki; Christina D Befani; Panagiotis Liakos; Christos N Papandreou
Journal:  Invest New Drugs       Date:  2013-05-05       Impact factor: 3.850

Review 6.  Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments.

Authors:  Mahmoud S Alghamri; Brandon L McClellan; Carson S Hartlage; Santiago Haase; Syed Mohd Faisal; Rohit Thalla; Ali Dabaja; Kaushik Banerjee; Stephen V Carney; Anzar A Mujeeb; Michael R Olin; James J Moon; Anna Schwendeman; Pedro R Lowenstein; Maria G Castro
Journal:  Front Pharmacol       Date:  2021-05-18       Impact factor: 5.988

7.  The Clinical and Prognostic Significance of Activated AKT-mTOR Pathway in Human Astrocytomas.

Authors:  Elias A El Habr; Christos Adamopoulos; Georgia Levidou; Aggeliki A Saetta; Penelope Korkolopoulou; Christina Piperi
Journal:  Neurol Res Int       Date:  2012-02-21

8.  Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1.

Authors:  Mahmoud S Alghamri; Rohit Thalla; Ruthvik P Avvari; Ali Dabaja; Ayman Taher; Lili Zhao; Peter J Ulintz; Maria G Castro; Pedro R Lowenstein
Journal:  Neurooncol Adv       Date:  2020-03-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.